Immutep Limited - American Depositary Shares (IMMP)
2.0300
+0.0500 (2.53%)
NASDAQ · Last Trade: May 16th, 8:25 PM EDT
Detailed Quote
Previous Close
1.980
Open
2.010
Bid
1.980
Ask
2.080
Day's Range
1.950 - 2.090
52 Week Range
1.320 - 3.335
Volume
107,536
Market Cap
1.52B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
611,636
Chart
About Immutep Limited - American Depositary Shares (IMMP)
Immutep Ltd is a biotechnology company that focuses on developing innovative immunotherapy treatments for cancer and autoimmune diseases. The company is primarily engaged in the research and development of products that harness the power of the immune system to better target and eliminate cancer cells. Immutep's pipeline includes both monoclonal antibodies and other therapeutic agents designed to enhance immune response, with an emphasis on delivering effective treatments for patients with unmet medical needs. Through partnerships and collaborations, Immutep aims to pioneer new approaches to cancer therapy and improve patient outcomes. Read More
SYDNEY, AUSTRALIA, May 15, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that a 60.8% response rate and 90.2% disease control rate, according to RECIST1.1, has been achieved in the investigator-initiated INSIGHT-003 trial as of the data-cut off date of 06 May 2025. INSIGHT-003 is evaluating eftilagimod alpha (efti) in combination with the anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer (1L NSCLC).
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer patients, with no new safety concerns.
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.
Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall response rate was observed in the Phase 2/3 trial.
